Replies to post #435945 on Amarin Corp Plc (AMRN)

[Number sleven]

Tatsumaki, Your history report is spot on.
"All Amarin had left was Reduce it, so they finished it out and tried to market that as an indication."
You say that as if you don't think that a CVD indication has any value. Sounds like you are saying that the TG reduction was the big money label?
Don't bother to respond. This isn't the beginning of a conversation.
Sleven,

[Whalatane]

Yes back in the Anchor days ...Lovaza was a big seller especially in Spain as Omacor ...and generously reimbursed at that time .
From Grok

Omacor saw significant global sales growth in the late 2000s. For instance, a 2008 report noted a 52% increase in global end-user sales for Omacor/Lovaza, reaching USD 778 million, with strong growth in major European markets, including Spain. Specifically, European sales grew by 34% to USD 289 million in 2008.

Vascepa ( AMR101 ) was seen by my Cardiologist , as something I could take to lower my TG;s ( in the low 200 mg/dl's ) that wouldn't have the risk of increasing my LDL cholesterol .
That was the big knock ...at the time ...on Lovaza .
It was also widely assumed that lowering high TG's would lower CV event risk .
The R-IT data showed us that TG lowering by itself .....was just a small part of the CV risk reduction benefit from taking Vascepa

Kiwi